ID   FR4
AC   CVCL_M505
SY   FR-4
DR   Cosmic; 720785
DR   Cosmic; 2081381
DR   Cosmic; 2367267
DR   GEO; GSM143352
DR   GEO; GSM290289
DR   Wikidata; Q54835150
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1697013;
RX   PubMed=10557056;
RX   PubMed=10936422;
RX   PubMed=11157491;
RX   PubMed=11429052;
RX   PubMed=12886255;
RX   PubMed=17171682;
RX   PubMed=17229644;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=18700954;
RX   PubMed=19306352;
RX   PubMed=32123307;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Population: Japanese.
CC   Characteristics: Produces IgA kappa.
CC   Doubling time: 131 hours (PubMed=1697013).
CC   Omics: Array-based CGH.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_M504 ! AD3 [Human myeloma]
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 29-06-23; Version: 18
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1697013;
RA   Tagawa S., Doi S., Taniwaki M., Abe T., Kanayama Y., Nojima J.,
RA   Matsubara K.-i., Kitani T.;
RT   "Amylase-producing plasmacytoma cell lines, AD3 and FR4, with
RT   der(14)t(8;14) and dic(8)t(1;8) established from ascites.";
RL   Leukemia 4:600-605(1990).
//
RX   PubMed=10557056; DOI=10.1038/sj.leu.2401563;
RA   Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A.,
RA   Shimizu S., Taniwaki M., Ueda R.;
RT   "Detection of MUM1/IRF4-IgH fusion in multiple myeloma.";
RL   Leukemia 13:1812-1816(1999).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11157491; DOI=10.1182/blood.V97.3.729;
RA   Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A.,
RA   Kuehl W.M., Bergsagel P.L.;
RT   "Activated fibroblast growth factor receptor 3 is an oncogene that
RT   contributes to tumor progression in multiple myeloma.";
RL   Blood 97:729-736(2001).
//
RX   PubMed=11429052; DOI=10.1111/j.1349-7006.2001.tb01142.x;
RA   Hanamura I., Iida S., Akano Y., Hayami Y., Kato M., Miura K.,
RA   Harada S., Banno S., Wakita A., Kiyoi H., Naoe T., Shimizu S.,
RA   Sonta S.-i., Nitta M., Taniwaki M., Ueda R.;
RT   "Ectopic expression of MAFB gene in human myeloma cells carrying
RT   (14;20)(q32;q11) chromosomal translocations.";
RL   Jpn. J. Cancer Res. 92:638-644(2001).
//
RX   PubMed=12886255; DOI=10.1038/sj.leu.2403026;
RA   Hayami Y., Iida S., Nakazawa N., Hanamura I., Kato M., Komatsu H.,
RA   Miura I., Dave B.J., Sanger W.G., Lim B., Taniwaki M., Ueda R.;
RT   "Inactivation of the E3/LAPTm5 gene by chromosomal rearrangement and
RT   DNA methylation in human multiple myeloma.";
RL   Leukemia 17:1650-1657(2003).
//
RX   PubMed=17171682; DOI=10.1002/gcc.20404;
RA   Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L.,
RA   Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D.,
RA   Lambertenghi-Deliliers G., Bertoni F., Neri A.;
RT   "Molecular characterization of human multiple myeloma cell lines by
RT   integrative genomics: insights into the biology of the disease.";
RL   Genes Chromosomes Cancer 46:226-238(2007).
//
RX   PubMed=17229644; DOI=10.3324/haematol.10300;
RA   Sanda T., Iida S., Kayukawa S., Ueda R.;
RT   "Induction of class II major histocompatibility complex expression in
RT   human multiple myeloma cells by retinoid.";
RL   Haematologica 92:115-120(2007).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C.,
RA   Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M.,
RA   Stewart A.K., Carpten J.D., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=18700954; DOI=10.1186/1755-8794-1-37;
RA   Ronchetti D., Lionetti M., Mosca L., Agnelli L., Andronache A.,
RA   Fabris S., Lambertenghi-Deliliers G., Neri A.;
RT   "An integrative genomic approach reveals coordinated expression of
RT   intronic miR-335, miR-342, and miR-561 with deregulated host genes in
RT   multiple myeloma.";
RL   BMC Med. Genomics 1:37.1-37.9(2008).
//
RX   PubMed=19306352; DOI=10.1002/gcc.20660;
RA   Lionetti M., Agnelli L., Mosca L., Fabris S., Andronache A.,
RA   Todoerti K., Ronchetti D., Lambertenghi-Deliliers G., Neri A.;
RT   "Integrative high-resolution microarray analysis of human myeloma cell
RT   lines reveals deregulated miRNA expression associated with allelic
RT   imbalances and gene expression profiles.";
RL   Genes Chromosomes Cancer 48:521-531(2009).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//